{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:00:42Z","timestamp":1784894442922,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020AAA0109501"],"award-info":[{"award-number":["2020AAA0109501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024ZD0520303"],"award-info":[{"award-number":["2024ZD0520303"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-015"],"award-info":[{"award-number":["2021-I2M-1-015"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-026-00947-3","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:06:32Z","timestamp":1779951992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRASG12V\/A146T mutations are associated with nCRT resistance via enhanced DNA double-strand break repair and support a deep learning prediction framework in LARC"],"prefix":"10.1186","volume":"31","author":[{"given":"Hengchang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"947_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S2468-1253(22)00156-X","volume":"7","author":"R Qu","year":"2022","unstructured":"Qu R, Ma Y, Zhang Z, Fu W. Increasing burden of colorectal cancer in China. Lancet Gastroenterol Hepatol. 2022;7:700.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"947_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA A Cancer J Clin"},{"key":"947_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM-K, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575\u201382.","journal-title":"Lancet Oncol"},{"key":"947_CR4","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1200\/JCO.2005.08.144","volume":"23","author":"J Folkesson","year":"2005","unstructured":"Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644\u201350.","journal-title":"J Clin Oncol"},{"key":"947_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795972","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, et al. Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.795972.","journal-title":"Front Immunol"},{"key":"947_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","volume":"8","author":"G Chen","year":"2023","unstructured":"Chen G, Jin Y, Guan W-L, Zhang R-X, Xiao W-W, Cai P-Q, et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023;8:422\u201331.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"947_CR7","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO.24.01160","volume":"42","author":"AJ Scott","year":"2024","unstructured":"Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol. 2024;42:3355\u201375.","journal-title":"J Clin Oncol"},{"key":"947_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.6004\/jnccn.2020.0032","volume":"18","author":"AB Benson","year":"2020","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw. 2020;18:806\u201315.","journal-title":"J Natl Compr Canc Netw"},{"key":"947_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638\u201346.","journal-title":"N Engl J Med"},{"key":"947_CR10","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926\u201333.","journal-title":"J Clin Oncol"},{"key":"947_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"R-D Hofheinz","year":"2012","unstructured":"Hofheinz R-D, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579\u201388.","journal-title":"Lancet Oncol"},{"key":"947_CR12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, R\u00f6del C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731\u201340.","journal-title":"N Engl J Med"},{"key":"947_CR13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","volume":"35","author":"T Conroy","year":"2024","unstructured":"Conroy T, Castan F, Etienne P-L, Rio E, Mesgouez-Nebout N, Evesque L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35:873\u201381.","journal-title":"Ann Oncol"},{"key":"947_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/bjs.8702","volume":"99","author":"ST Martin","year":"2012","unstructured":"Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918\u201328.","journal-title":"Br J Surg"},{"key":"947_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30097","volume":"3","author":"A Kasi","year":"2020","unstructured":"Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer. JAMA Netw Open. 2020;3:e2030097.","journal-title":"JAMA Netw Open"},{"key":"947_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/kjm2.12161","volume":"36","author":"M Huang","year":"2019","unstructured":"Huang M, Huang C, Wang J. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Kaohsiung J Med Sci. 2019;36:152\u20139.","journal-title":"Kaohsiung J Med Sci"},{"key":"947_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35511-y","author":"H Wang","year":"2022","unstructured":"Wang H, Jia H, Gao Y, Zhang H, Fan J, Zhang L, et al. Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-022-35511-y.","journal-title":"Nat Commun"},{"key":"947_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/rg.303095085","volume":"30","author":"B Barbaro","year":"2010","unstructured":"Barbaro B, Vitale R, Leccisotti L, Vecchio FM, Santoro L, Valentini V, et al. Restaging locally advanced rectal cancer with MR imaging after chemoradiation therapy. Radiographics. 2010;30:699\u2013716.","journal-title":"Radiographics"},{"key":"947_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/SLA.0b013e3181b91e63","volume":"250","author":"MF Kalady","year":"2009","unstructured":"Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250:582\u20139.","journal-title":"Ann Surg"},{"key":"947_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1148\/radiol.11102467","volume":"260","author":"L Curvo-Semedo","year":"2011","unstructured":"Curvo-Semedo L, Lambregts DMJ, Maas M, Thywissen T, Mehsen RT, Lammering G, et al. Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy\u2014Conventional MR volumetry versus diffusion-weighted MR imaging. Radiology. 2011;260:734\u201343.","journal-title":"Radiology"},{"key":"947_CR21","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/annonc\/mds010","volume":"23","author":"R Glynne-Jones","year":"2012","unstructured":"Glynne-Jones R, Anyamene N, Moran B, Harrison M. Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation? Ann Oncol. 2012;23:2517\u201326.","journal-title":"Ann Oncol"},{"key":"947_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00423-012-0929-5","volume":"397","author":"M Grade","year":"2012","unstructured":"Grade M, Wolff HA, Gaedcke J, Ghadimi BM. The molecular basis of chemoradiosensitivity in rectal cancer:implications for personalized therapies. Langenbecks Arch Surg. 2012;397:543\u201355.","journal-title":"Langenbecks Arch Surg"},{"key":"947_CR23","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.7150\/thno.37794","volume":"9","author":"J Yang","year":"2019","unstructured":"Yang J, Lin Y, Huang Y, Jin J, Zou S, Zhang X, et al. Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy. Theranostics. 2019;9:6856\u201366.","journal-title":"Theranostics"},{"key":"947_CR24","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1158\/1078-0432.CCR-10-2915","volume":"17","author":"KH Brettingham-Moore","year":"2011","unstructured":"Brettingham-Moore KH, Duong CP, Greenawalt DM, Heriot AG, Ellul J, Dow CA, et al. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin Cancer Res. 2011;17:3039\u201347.","journal-title":"Clin Cancer Res"},{"key":"947_CR25","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1200\/JCO.2005.00.406","volume":"23","author":"BM Ghadimi","year":"2005","unstructured":"Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005;23:1826\u201338.","journal-title":"J Clin Oncol"},{"key":"947_CR26","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1158\/0008-5472.CAN-05-3834","volume":"66","author":"T Watanabe","year":"2006","unstructured":"Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, Tanaka J, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 2006;66:3370\u20134.","journal-title":"Cancer Res"},{"key":"947_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cgh.2007.10.022","volume":"6","author":"C Rimkus","year":"2008","unstructured":"Rimkus C, Friederichs J, Boulesteix A, Theisen J, Mages J, Becker K, et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol. 2008;6:53\u201361.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"947_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41551-020-00682-w","volume":"5","author":"MY Lu","year":"2021","unstructured":"Lu MY, Williamson DFK, Chen TY, Chen RJ, Barbieri M, Mahmood F. Data-efficient and weakly supervised computational pathology on whole-slide images. Nat Biomed Eng. 2021;5:555\u201370.","journal-title":"Nat Biomed Eng"},{"key":"947_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2020.104003","volume":"126","author":"I Pacal","year":"2020","unstructured":"Pacal I, Karaboga D, Basturk A, Akay B, Nalbantoglu U. A comprehensive review of deep learning in colon cancer. Comput Biol Med. 2020;126:104003.","journal-title":"Comput Biol Med"},{"key":"947_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41416-024-02573-2","volume":"130","author":"H Xiao","year":"2024","unstructured":"Xiao H, Weng Z, Sun K, Shen J, Lin J, Chen S, et al. Predicting 5-year recurrence risk in colorectal cancer: development and validation of a histology-based deep learning approach. Br J Cancer. 2024;130:951\u201360.","journal-title":"Br J Cancer"},{"key":"947_CR31","doi-asserted-by":"publisher","first-page":"e763","DOI":"10.1016\/S2589-7500(21)00180-1","volume":"3","author":"M Bilal","year":"2021","unstructured":"Bilal M, Raza SEA, Azam A, Graham S, Ilyas M, Cree IA, et al. Development and validation of a weakly supervised deep learning framework to predict the status of molecular pathways and key mutations in colorectal cancer from routine histology images: a retrospective study. Lancet Digit Health. 2021;3:e763\u201372.","journal-title":"Lancet Digit Health"},{"key":"947_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.compmedimag.2021.101861","volume":"88","author":"C Zhou","year":"2021","unstructured":"Zhou C, Jin Y, Chen Y, Huang S, Huang R, Wang Y, et al. Histopathology classification and localization of colorectal cancer using global labels by weakly supervised deep learning. Comput Med Imaging Graph. 2021;88:101861.","journal-title":"Comput Med Imaging Graph"},{"key":"947_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216078","volume":"557","author":"J Li","year":"2023","unstructured":"Li J, Song C, Gu J, Li C, Zang W, Shi L, et al. RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance. Cancer Lett. 2023;557:216078.","journal-title":"Cancer Lett"},{"key":"947_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60228-z","author":"L Mi","year":"2025","unstructured":"Mi L, Cai Y, Qi J, Chen L, Li Y, Zhang S, et al. Elevated nonhomologous end-joining by AATF enables efficient DNA damage repair and therapeutic resistance in glioblastoma. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-60228-z.","journal-title":"Nat Commun"},{"key":"947_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104240","volume":"194","author":"AS Kushwah","year":"2024","unstructured":"Kushwah AS, Masood S, Mishra R, Banerjee M. Genetic and epigenetic alterations in DNA repair genes and treatment outcome of chemoradiotherapy in cervical cancer. Crit Rev Oncol Hematol. 2024;194:104240.","journal-title":"Crit Rev Oncol Hematol"},{"key":"947_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01441-4","author":"G Zhu","year":"2021","unstructured":"Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021. https:\/\/doi.org\/10.1186\/s12943-021-01441-4.","journal-title":"Mol Cancer"},{"key":"947_CR37","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1158\/1078-0432.CCR-10-2273","volume":"17","author":"PP Grimminger","year":"2011","unstructured":"Grimminger PP, Danenberg P, Dellas K, Arnold D, R\u00f6del C, Machiels J-P, et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res. 2011;17:3469\u201377.","journal-title":"Clin Cancer Res"},{"key":"947_CR38","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","volume":"28","author":"WK Chatila","year":"2022","unstructured":"Chatila WK, Kim JK, Walch H, Marco MR, Chen CT, Wu F, et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat Med. 2022;28:1646\u201355.","journal-title":"Nat Med"},{"key":"947_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/jso.26244","volume":"123","author":"P Zhou","year":"2020","unstructured":"Zhou P, Goffredo P, Ginader T, Thompson D, Hrabe J, Gribovskaja-Rupp I, et al. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer. J Surg Oncol. 2020;123:278\u201385.","journal-title":"J Surg Oncol"},{"key":"947_CR40","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1245\/s10434-016-5205-4","volume":"23","author":"OS Chow","year":"2016","unstructured":"Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, et al. KRAS and combined KRAS\/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy. Ann Surg Oncol. 2016;23:2548\u201355.","journal-title":"Ann Surg Oncol"},{"key":"947_CR41","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1245\/s10434-013-2910-0","volume":"20","author":"MP Duldulao","year":"2013","unstructured":"Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, et al. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol. 2013;20:2166\u201371.","journal-title":"Ann Surg Oncol"},{"key":"947_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s13304-015-0281-8","volume":"67","author":"J Martellucci","year":"2015","unstructured":"Martellucci J, Alemanno G, Castiglione F, Bergamini C, Valeri A. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. Updates Surg. 2015;67:47\u201353.","journal-title":"Updates Surg"},{"key":"947_CR43","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1158\/2326-6066.CIR-17-0630","volume":"6","author":"D Ji","year":"2018","unstructured":"Ji D, Yi H, Zhang D, Zhan T, Li Z, Li M, et al. Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy. Cancer Immunol Res. 2018;6:1401\u201316.","journal-title":"Cancer Immunol Res"},{"key":"947_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003840050072","volume":"12","author":"O Dworak","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19\u201323.","journal-title":"Int J Colorectal Dis"},{"key":"947_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.02.004","volume":"14","author":"H Zhang","year":"2024","unstructured":"Zhang H, Li Q, Guo X, Wu H, Hu C, Liu G, et al. MGMT activated by Wnt pathway promotes cisplatin tolerance through inducing slow-cycling cells and nonhomologous end joining in colorectal cancer. J Pharm Anal. 2024;14:100950.","journal-title":"J Pharm Anal"},{"key":"947_CR46","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1002\/cam4.2203","volume":"8","author":"X Yan","year":"2019","unstructured":"Yan X, Chen J, Meng Y, He C, Zou S, Li P, et al. RAD18 may function as a predictor of response to preoperative concurrent chemoradiotherapy in patients with locally advanced rectal cancer through caspase-9-caspase-3-dependent apoptotic pathway. Cancer Med. 2019;8:3094\u2013104.","journal-title":"Cancer Med"},{"key":"947_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/35094067","volume":"1","author":"R Fodde","year":"2001","unstructured":"Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1:55\u201367.","journal-title":"Nat Rev Cancer"},{"key":"947_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-pathol-011110-130235","volume":"6","author":"ER Fearon","year":"2011","unstructured":"Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis. 2011;6:479\u2013507.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"947_CR49","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1038\/s41388-020-1245-0","volume":"39","author":"S Zhou","year":"2020","unstructured":"Zhou S, Liu S, Lin C, Li Y, Ye L, Wu X, et al. TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ. Oncogene. 2020;39:3710\u201325.","journal-title":"Oncogene"},{"key":"947_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11605-022-05409-7","volume":"27","author":"A Wang","year":"2023","unstructured":"Wang A, Ding R, Zhang J, Zhang B, Huang X, Zhou H. Machine learning of histomorphological features predict response to neoadjuvant therapy in locally advanced rectal cancer. J Gastrointest Surg. 2023;27:162\u20135.","journal-title":"J Gastrointest Surg"},{"key":"947_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/sj.bjc.6604439","volume":"99","author":"F Cappuzzo","year":"2008","unstructured":"Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008;99:83\u20139.","journal-title":"Br J Cancer"},{"key":"947_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1148\/radiol.211986","volume":"303","author":"J Shin","year":"2022","unstructured":"Shin J, Seo N, Baek S-E, Son N-H, Lim JS, Kim NK, et al. MRI radiomics model predicts pathologic complete response of rectal cancer following chemoradiotherapy. Radiology. 2022;303:351\u20138.","journal-title":"Radiology"},{"key":"947_CR53","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00259-018-4250-6","volume":"46","author":"V Giannini","year":"2019","unstructured":"Giannini V, Mazzetti S, Bertotto I, Chiarenza C, Cauda S, Delmastro E, et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features. Eur J Nucl Med Mol Imaging. 2019;46:878\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"947_CR54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11605-022-05477-9","volume":"27","author":"KJ Peterson","year":"2023","unstructured":"Peterson KJ, Simpson MT, Drezdzon MK, Szabo A, Ausman RA, Nencka AS, et al. Predicting neoadjuvant treatment response in rectal cancer using machine learning: evaluation of MRI-based radiomic and clinical models. J Gastrointest Surg. 2023;27:122\u201330.","journal-title":"J Gastrointest Surg"},{"key":"947_CR55","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2589-7500(21)00215-6","volume":"4","author":"L Feng","year":"2022","unstructured":"Feng L, Liu Z, Li C, Li Z, Lou X, Shao L, et al. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. Lancet Digit Health. 2022;4:e8\u201317.","journal-title":"Lancet Digit Health"},{"key":"947_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-021-03911-z","author":"J Peng","year":"2021","unstructured":"Peng J, Lv J, Peng J. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis. Int J Colorectal Dis. 2021. https:\/\/doi.org\/10.1007\/s00384-021-03911-z.","journal-title":"Int J Colorectal Dis"},{"key":"947_CR57","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-19-0908","volume":"25","author":"SC Kamran","year":"2019","unstructured":"Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, et al. Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer. Clin Cancer Res. 2019;25:5561\u201371.","journal-title":"Clin Cancer Res"},{"key":"947_CR58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.radonc.2009.10.001","volume":"94","author":"J Gaedcke","year":"2010","unstructured":"Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol. 2010;94:76\u201381.","journal-title":"Radiother Oncol"},{"key":"947_CR59","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2159-8290.CD-19-0406","volume":"9","author":"GA Hobbs","year":"2019","unstructured":"Hobbs GA, Der CJ. RAS mutations are not created equal. Cancer Discov. 2019;9:696\u20138.","journal-title":"Cancer Discov"},{"key":"947_CR60","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/1078-0432.CCR-11-3210","volume":"18","author":"Y Imamura","year":"2012","unstructured":"Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012;18:4753\u201363.","journal-title":"Clin Cancer Res"},{"key":"947_CR61","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1200\/PO.21.00223","volume":"5","author":"I van\u2019t Erve","year":"2021","unstructured":"van\u2019t Erve I, Wesdorp NJ, Medina JE, Ferreira L, Leal A, Huiskens J, et al. A146 mutations are associated with distinct clinical behavior in patients with colorectal liver metastases. JCO Precis Oncol. 2021;5:1758\u201367.","journal-title":"JCO Precis Oncol"},{"key":"947_CR62","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jmoldx.2018.09.007","volume":"21","author":"M Alcaide","year":"2019","unstructured":"Alcaide M, Cheung M, Bushell K, Arthur SE, Wong H-L, Karasinska J, et al. A novel multiplex droplet digital PCR assay to identify and quantify KRAS mutations in clinical specimens. J Mol Diagn. 2019;21:214\u201327.","journal-title":"J Mol Diagn"},{"key":"947_CR63","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1373\/jalm.2018.026278","volume":"3","author":"MR Al-Turkmani","year":"2018","unstructured":"Al-Turkmani MR, Godwin KN, Peterson JD, Tsongalis GJ. Rapid somatic mutation testing in colorectal cancer by use of a fully automated system and single-use cartridge: a comparison with next-generation sequencing. J Appl Lab Med. 2018;3:178\u201384.","journal-title":"J Appl Lab Med"},{"key":"947_CR64","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cell.2015.05.053","volume":"162","author":"F Dietlein","year":"2015","unstructured":"Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, et al. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell. 2015;162:146\u201359.","journal-title":"Cell"},{"key":"947_CR65","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10549-018-05079-7","volume":"174","author":"PH Dinkelborg","year":"2019","unstructured":"Dinkelborg PH, Wang M, Gheorghiu L, Gurski JM, Hong TS, Benes CH, et al. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. Breast Cancer Res Treat. 2019;174:605\u201313.","journal-title":"Breast Cancer Res Treat"},{"key":"947_CR66","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1158\/0008-5472.CAN-18-3959","volume":"79","author":"J Erber","year":"2019","unstructured":"Erber J, Steiner JD, Isensee J, Lobbes LA, Toschka A, Beleggia F, et al. Dual inhibition of GLUT1 and the ATR\/CHK1 kinase axis displays synergistic cytotoxicity in KRAS-mutant cancer cells. Can Res. 2019;79:4855\u201368.","journal-title":"Can Res"},{"key":"947_CR67","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1054\/bjoc.2001.1964","volume":"85","author":"HJN Andreyev","year":"2001","unstructured":"Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the \u2018RASCAL II\u2019 study. Br J Cancer. 2001;85:692\u20136.","journal-title":"Br J Cancer"},{"key":"947_CR68","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/gcc.20854","volume":"50","author":"CP Vaughn","year":"2011","unstructured":"Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chrom Cancer. 2011;50:307\u201312.","journal-title":"Genes Chrom Cancer"},{"key":"947_CR69","first-page":"6750","volume":"60","author":"S Guerrero","year":"2000","unstructured":"Guerrero S, Casanova I, Farr\u00e9 L, Mazo A, Capell\u00e0 G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60:6750\u20136.","journal-title":"Cancer Res"},{"key":"947_CR70","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1001\/jama.2010.1535","volume":"304","author":"W De Roock","year":"2010","unstructured":"De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with Cetuximab. JAMA. 2010;304:1812.","journal-title":"JAMA"},{"key":"947_CR71","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/14737159.2023.2268008","volume":"23","author":"N Raei","year":"2023","unstructured":"Raei N, Safaralizadeh R, Latifi-Navid S. Clinical application of circulating tumor DNA in metastatic cancers. Expert Rev Mol Diagn. 2023;23:1209\u201320.","journal-title":"Expert Rev Mol Diagn"},{"key":"947_CR72","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.3390\/cancers13143378","volume":"13","author":"J Milin-Lazovic","year":"2021","unstructured":"Milin-Lazovic J, Madzarevic P, Rajovic N, Djordjevic V, Milic N, Pavlovic S, et al. Meta-analysis of circulating cell-free DNA\u2019s role in the prognosis of pancreatic cancer. Cancers. 2021;13:3378.","journal-title":"Cancers"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00947-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00947-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00947-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:01:31Z","timestamp":1784890891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00947-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00947-3","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involving human participants was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences (approval no. NCC2023 C-248). Written informed consent was obtained from all individual participants included in the study. All animal experiments were performed in compliance with the International Council for Laboratory Animal Science (ICLAS) guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) of the National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences (approval no. NCC2023A179).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"120"}}